Return to homepage Skip to navigation Skip to site search Skip to main content Skip to footer

Prof Nikolai Zhelev

Role: Director Of CMCBR

Division: Division of Science

School/Department: School of Science, Engineering & Tech

Telephone Number: +44 (0)1382 308536



I am Professor of Medical Biotechnology at the School of Science, Engineering and Technology.My laboratory conducts research in the fields of drug development, cancer and cardiovascular systems biology and nanobiotechnology. My group collaborate with several biotech companies and research groups in UK, Europe, Canada and China. I am also involved in undergraduate and postgraduate teaching and project supervision. My laboratory offers research projects for Honours, MSc, MbRes, MPhil and PhD students.



Module title: Test Tube to Tablet (LSC305)

Module title: Advanced Systems Biology (LSC405)

Module title: Industrial/Biomedical Biotechnology (BI1103) – for MSc

Module title: Industrial/Biomedical Biotechnology (BI1104) – for BSc

Module title: Professional Studies (BI0704A)

Module title: Adult Nursing (HE0808A)

Module title: Human Biology 3 (HE0852A)

Module title: Systems Biology in Biomedicine (BI1013A)

Module title: Clinical Biochemistry and Cellular Pathology (HS0905A)

Module title: Life Sciences Industry Perspectives (BI0914A)

Module title: Contemporary and Industrial Biotechnology and Biomedical Science (BI1004A)


Module title: Techniques and Skills (BI0703A)

Module title: Project Skills (BI1009A)

Module title: BMS Honours Projects (BI1008A)


Module title: Principles of biology (BI0701A)


The research in my laboratory aims to understand the regulation of the signal transduction pathways related to tumorigenesis, through the development of methods that can provide quantitative information about the complex interactions of such pathways in real time in a single cell. We have developed the first live-cell biosensor for monitoring activity on cancer targets such as cyclin-dependent kinases in tumours. In addition, we are working with biopharmaceutical and biotech companies on the development of novel drugs against cancer and cardiac hypertrophy and novel nanobiotechnology tools to study molecular interactions.

We are collaborating and publishing joint papers with a number of research institutions including: Harvard Medical School, University of Edinburgh,  A* STAR Singapore, University of Namur, University of Liege, Medical University Sofia, Medical University Plovdiv, Technical University Varna, Sofia University,  Trakia University,  University of Dundee, The Roslin Institute and Royal School of Veterinary Sudies, St James’s University Hospital Leeds, Howard Hughes Medical Institute, Novartis Institutes for Biomedical Research and Dana-Farber Cancer Institute. We are also working with industrial partners namely:  Cyclacel Pharmaceuticals Inc., Scientific Technological Service (STS) Ltd. and  Norton Scientific Inc.


Books and books chapters:

Zhelev N., Trifonov D., Wang S., Hassan M., El Serafi I., Mitev V. Seliciclib – discovery and development. 2016, DSP, Dundee, Edinburgh, London

Trifonov D., Zhelev N. Drug discovery and development. In Current applications of biotechnology. 2015, Erciyes University, p 273

Bown J., Deeni Y., Goltsov A., Khalil H., Isaacs J., Li Y., Sampson A.T., Savage A., Zhelev N. Cancer systems biology: integrating experimental and theoretical systems at cellular and tissue scales. In Current applications of biotechnology. 2015,Erciyes University, p 357

Khalil H.S, Chakarov S., Zhelev N. ATM - a damage sensor and cancer target. 2014, DSP, Dundee, Edinburgh, London

Chakarov S., Petkova R., Russev G. Zhelev N. DNA repair and individual repair capacity. 2014, DSP, Dundee, Edinburgh, London

White R., Zhelev N., Bradley D. Issues of Innovation, Design and Development in Relation to the Implementation of Light Scattering Instrumentation. In Mechatronics and manufacturing engineering (J.P. Davim ed.) 2012, Woodhead Publishing, Cambridge, p 1

Vlaykova T., Gulubova M., Yovchev Y., Dimov D., Vlaykova D., Chilingirov P., Zhelev N. Glutathione-S-transferases in development, progression and therapy of colorectal cancer  In Colorectal Cancer / Book 1. 2011, Intech Open Access Publisher, Rijeka p 81

Todorov, I.T., Zhelev N.Zh., Philipova, R.N., Hadjiolov, A.A. 1990 Synthesis and phosphorylation of the 125 kDa nuclear matrix protein mitotin during the cell cycle. In Nuclear structure and function (I.B.Zbarsky and J.R.Harris, eds), Plenum London, p 323.


Research Articles and Patents (granted):

Zhelev N, Kaske R, Bown J. Validation of a novel assay for cardiology drug screening using hESC-derived cardiomyocyte spheroids - "Mini-hearts". J Biotechnol 2016 vol 231 p 108

Zhelev N. Next-generation technologies to develop new therapeutics in oncology and cardiology. J Biotechnol 2016 vol 231 p 4

Zhelev N, Reynolds L, Kuzmanova E. Study of the effect of novel CDK9 inhibitor on in vitro-induced hypertrophy in human stem-cells-derived cardiomyocytes. J Biotechnol 2016 vol 231 p 107

Petkova R, Dimitrova V, Zhelev N, Chakarov S. An old wives' tale. Reproductive outcomes in pregnant women aged 35 or older: the role of individual repair capacity. Biodiscovery 2016; vol 18: 2

Lewis K, Reynolds L, Kuzmanova E, Zhelev N. Evaluation of the therapeutic potential of a CDK9-inhibiting compound in human hypertrophic cardiomyopathy using hESC-derived cardiomyocytes.  J Biotechnol Biomater 2015; vol 5(2) p 64

Khalil HS, Mitev V, Vlaykoya T, Cayicchi L, Zhelev N. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance. J Biotechnol 2015 vol 202 p 40

Zhelev N. Novel stem-cell-based approaches in the development of cyclin-dependent kinase inhibitors as new therapeutics in cardiology. J Biotechnol Biomater 2015; vol 5(2) p 32

Arabadjiev A, Petkova R, Chakarov S, Pankov R, Zhelev N. We heart cultured hearts. A comparative review of methodologies for targeted differentiation and maintenance of cardiomyocytes derived from pluripotent and multipotent stem cells. Biodiscovery 2014; vol 14, 2

Chakarov S, Petkova R, Russev GCh, Zhelev N. DNA damage and the circadian clock. Biodiscovery 2014; vol 13, 1

Bown JL., Idowu MA., Khalil HS, Goltsov A., Deeni Y., Zhelev N., Langdon SP., Harrison DJ. Process-based vs. data-driven modelling of cancer cell behavior. J Biotechnol 2014 vol 185 p13

Chakarov S, Petkova R, Russev GCh, Zhelev N. DNA repair and carcinogenesis. Biodiscovery 2014; vol 12, 1

Zhelev N, Oluwaseun O.A., Uth K, D' Ascanio I., Stoyanova V.,  Vlaykova T.,  Mitev V. Systems biology approach in the discovery and development of cyclin-dependent kinase inhibitors  as new therapeutics in oncology and cardiology.  J Biotechnol Biomater 2014, vol. 3(5) p 81

Chakarov S, Petkova R, Russev GCh, Zhelev N. DNA damage and mutation. Types of DNA damage. Biodiscovery 2014; vol 11, 1

Zhelev N., Tupone MG., Cecceroni L., Cavicchi L., D’Ascanio I., Khalil HS., Uth K., Mitev V. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance. J Biotechnol 2014 vol 185 p10

Zhelev N., Trifonov D., Wang S., Hassan M., El Serafi I., Mitev V. From Roscovitine to CYC202 to Seliciclib – from bench to bedside: discovery and development. Biodiscovery 2013 vol 10, 1.

Zhelev N., Tummala H., Trifonov D., D' Ascanio I., Oluwaseun O.A., Fischer P.M. Recent advances in the development of cyclin-dependent kinase inhibitors as new therapeutics in oncology and cardiology.  Curr Opin Biotech 2013 vol 24(1) p 25

Khalil HS., Idowu M., Bown J., Zhelev N. Reverse engineering of drug induced DNA damage response signalling pathway reveals dual outcomes of ATM kinase inhibition. Biodiscovery 2013 vol 9, 4

Khalil H.S., Tummala H., DeCaris L., Zhelev N. Pharmacological inhibition of ATM results in mitochondrial biogenesis in AMPK independent manner. Cancer Res 2013 vol 73(8) p 1697

Zhelev N., Khalil HS., White R. New approaches to rapid screening for protein aggregates by light scattering. Biotechnol & Biotechnol Eq. 2013 vol 27(6), 4327.

Chelenkova P., Petkova R., D' Ascanio I., Zhelev N., Chakarov S. In sickness and in health: a set of markers for individual repair capacity in risk assessment, monitoring and prognosis of human disease. Curr Opin Biotech 2013 vol 24(1) p 105

Tummala H., Khalil HS., Islam R., Jones SJ., Ellis IR., D’Ascanio I., Zhelev N., Lester DH. The alternate GNB3 splice variant, Gβ3s, exhibits an altered signalling response to EGF stimulation, which leads to enhanced cell migration. Biodiscovery 2013 vol 9, 3.

Trifonov D, Tummala H., Clements S., Zhelev N. Effect of roscovitine on cardiac hypertrophy in human stem cell derived cardiomyocytes. Curr Opin Biotech 2013 vol 24(1) p 114.

Khalil H.S., Tummala H., Zhelev N. ATM in focus: A damage sensor and cancer target. Biodiscovery 2012 vol 5, 1

Tummala H., Khalil H.S., Mitev V., Zhelev N, A quantitative integrated systems biology approach for modeling cell cycle pathways in normal and tumor cells. Cancer Res 2012 vol 72(8) p 4913

Khalil, H.S., Tummala H., Zhelev N. Phosphorylated ATM at S-1981 (pATM) undergoes COPI mediated Golgi export upon DNA damage. FEBS J 2012 vol 279(S1) p 146

Tummala H, Khalil HS, Mitev V, Zhelev N, A quantitative integrated systems biology approach for modeling cell cycle pathways in normal and tumor cells. Cancer Res 2012 vol 72(8) p 4913

Khalil H.S., Tummala H., Chakarov S,. Zhelev N., Lane D.P. Targeting ATM pathway for therapeutic intervention in cancer. Biodiscovery 2012 vol 1, 3

Khalil, HS, Tummala H, Zhelev N. Differences in the DDR enzymes activation kinetics between normal and cancer cells could be utilized to achieve targeted cellular sensitivity towards genotoxic agents. Cancer Res 2012 vol 72(8) p 3103

Khalil, HS, Tummala H, Zhelev N. Phosphorylated ATM at S-1981 (pATM) undergoes COPI mediated Golgi export upon DNA damage. FEBS J 2012 vol 279(S1) p 146

Tummala H, Khalil HS, DAscanio I, Wehner D, Lester DH, Babraj J, Zhelev N. Human 825C>T polymorphism in GNB3 gene promotes enhanced cell migration by inducing cytosolic calcium influx and hyper phosphorylation of ERK regulated mTOR pathway. FEBS J 2012 vol 279(S1) p 141

Idowu M.A., Bown L., Zhelev. A new method for identifying a data-consistent self-reconfigurable predictive bio-network model of the cell cycle based on time series data and its application in cancer systems biology. Cancer Res 2012 vol 72(8) p 4921

Khalil HS, Tummala H, Hupp TR, Zhelev N. Pharmacological inhibition of ATM by KU55933 stimulates ATM transcription  Exp. Biol. Med 2012 vol  237(6) p 622 

Mustaffa M, Zhelev N. You cannot always win: molecular bases of the resistance of picornaviruses to WIN compounds. Biotech & Biotech Eq. 2012 vol 26(2) p 2826

Zhelev N. Man of Science: Celebrating Professor Sir David Lane’s 60th anniversary. Biodiscovery 2012 vol 1, 3

Khalil HS, Petkova R, Zhelev N. Differential genetic advantages in youth and in aging, or how to die healthy.  Biotech & Biotech Eq  2012 vol 26(1) p 2703

Petkova R, Tummala H, Zhelev N. Nothing in excess – lessons learned from the expression of high-mobility group proteins type A in non-cancer and cancer cells. Biotech & Biotech Eq  2011  vol 25(4) p 2572

Zhelev N. The “golden age” of biotechnology in Europe. Biotech & Biotech Eq  2011  vol 25(4) p 2688

Tummala H; Fleming S; Hocking PM; Ali M; Inglehearn CF; Zhelev N; Lester DH. Mutant GNB3 gene mediates aberrant signalling events leading to renal and visual anomalies in rge chickens.  PLoS  2011 vol 6 (8) p 21156

Tummala H, Khalil HS, Nikolova E, Mitev V, Zhelev N. Cell-based nanosensors for systems biology research and drug development. Curr Opin Biotech 2011 vol 22(1) p 25

Tummala H, Khalil HS, Zhelev N. Repair, abort, ignore? Strategies for dealing with UV damage. Biotech & Biotech Eq. 2011  vol 25(3) p 2443

Clyde RG, Tummala H, Khalil HS, Goszcz K, Lucka I, Tupone MG, Zwirek M, Cavicchi L, Vallatur J, Stoyanova V, Mitev V, Zhelev N (2011). A novel quantitative systems biology approach to cancer research and treatment. Curr Opin Biotech 2011 vol 22(1) p 58

Khalil HS, Tummala H, Omoboye AO, Zhelev N. Novel insights of ATM regulation and its potential as a target for therapeutic intervention in cancer  Curr Opin Biotech 2011 vol 22(1) p 115

Idowu MA,  Goltsov A, Khalil HS, Tummala H, Zhelev N, Bown J. Cancer research and personalized medicine: a new approach to modeling time-series data using analytical methods and Half systems. Curr Opin Biotech  2011 vol 22(1) p 59

Stoyanova V, Zhelev N, Ghenev E, Bosheva M.Assessment of left ventricular structure and function in rats subjected to pressure-overload hypertrophy in time. Kardiol Pol 2009 ;vol 67(1) p 2 

M. Peter Fischer, Nikolai Zhelev. Antennapedia homeodomain helix 3 derived translocation vectors. EP1135410 B1; Dec 31, 2008

Stoyanova V, Zhelev N. Alterations in protein P53 expression during the development of pressure overload-induced left  ventricular hypertrophy in rats. Biotechnol. & Biotechnol Eq 2008 vol. 22 (4) p 977

Atanasova G, Isaeva A, Zhelev N, Poumay Y, V Mitev. Effect of the CDK-inhibitor CYC202 on p38MAPK, ERK ½ , c-Myc activities and proliferation of papillomavirus type 16 E6E7-transformed keratinocytes. Oncology Reports 2007 vol. 18, (4)  p 999

Nikolova E, Mitev V, Zhelev N, Deroanne CF, Poumay Y. The small Rho GTPase Rac1 controls normal human dermal fibroblasts proliferation with phosphorylation of the oncoprotein c-myc. Biochem Biophys Res Commun 2007 vol 359: p 834

Neychev VK, Nikolova E, Zhelev N, Mitev VI. Saponins from Tribulus terrestris L are less toxic for normal human fibroblasts than for many cancer lines: influence on apoptosis and proliferation. Experimental Biology and Medicine 2007 vol  232 (1) p 126

Peter M. Fischer, Nikolai Zhelev, Shudong Wang. Forms of membrane transport vector penetratin; a membrane translocation peptide carrier moiety of given amino acid sequence; use in the improved delivery of therapeutic agents into target cells. US7153931 B1; Dec 26, 2006

Miteva L, Zhelev N, Mitev V. Molecular targets for hyperproliferating skin diseases. Allergy Hypersensitivity Asthma  2006 vol 4 p 2 

Clyde R.G,, Bown J.L, Hupp T.R, Zhelev N, Crawford J.W. The role of modeling in identifying drug targets for diseases of the cell cycle. J. R. Soc Interface 2006 vol. 3(10) p 617

Peter Martin Fischer, Nikolai Zhelev. Drug delivery; peptide carrier is linked via oligonucleotides, nucleotides, proteins, or peptides to drugs (anticancer agents, antitumor agents- paclitaxel and/or popdphyllotoxin). US7101967 B2; Sep 5, 2006

Stoyanova V, Dobreva B, Ghenev E, Zhelev N. In vivo assessment of left ventricular hypertrophy in rats: necropsy validation. Biotechnol. & Biotechnol Eq 2006 vol. 20 (2) p 12 

Wang S, Zhelev N.Z, Duff S, Fischer P.M. Synthesis and biological activity of conjugates between paclitaxel and the cell delivery vector penetratin. Bioorg Med Chem Lett. 2006 vol. 16(10) p 2628

Peter M. Fischer, Shudong Wang, Nikolai Zhelev. Drug moiety linked to a carrier moiety comprising a homeobox peptide or a fragment or derivative thereof. US6992169 B2; Jan 31, 2006

Zhelev N., Barudov S. Laser light scattering applications in biotechnology. Biotechnol & Biotechnol Eq 2005 vol. 19 (3) p 3

Stoyanova V.K, Zhelev N.Z., Yanev I.B, Ghenev E.D, Nachev C.K Time course and progression of pressure overload-induced cardiac hypertrophy in rats. Folia Med 2005 vol. 47(2) p 52

Atanasova G, Jans R, Zhelev N, Mitev V, Poumay Y. Effects of the cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) on the physiology of cultured human keratinocytes. Biochem Pharmacol. 2005 vol. 70(6) p 824

Zhelev N, Neichev V. The significance of the type quality and form of the carbohydrate intake for the optimum re-synthesis of the muscular glycogen during the first restoration phase.  Medicine and Sport  2005 vol. 2 p 32

Zhang GJ., Safran M, Wei W, Sorensen E, Lassota P, Zhelev N, Neuberg D.S, Shapiro G, Kaelin W.G Jr. Bioluminescent imaging of Cdk2 inhibition in vivo. Nature Medicine 2004  vol. 10(6) p 643

Neichev V.K, Nikolova E.M, Zhelev N, Mitev V.I. Investigation of the influence of Tribulus terrestris extract on proliferation of normal human skin fibroblasts.  Oncologos 2004 vol. 1 p 89

Atanasova G, Jans R, Zhelev N, Mitev V, Poumay Y.G.. Cell cycle arrest by CDK inhibitor CYC202 (R-roscovitine) in normal human keratinocytes is followed by induction of p38 MAPK phosphorylation and subsequent involucrin expression. on the physiology of cultured human keratinocytes. Journal of Investigative Dermatology. 2004 vol. 122(3) p 95

Isaeva A.P. Petrov S, Zhelev N. Effect  of polyamines on the proliferation of normal and cancer cells. Isaeva A.P, Petrov S, Zhelev N. Effect of polyamines on proliferation of normal and tumour  cells Oncologos 2004 vol. 1 p 83

Sarek J, Klinot J, Dzubak P, Klinotova E, Noskova V, Krecek V, Korinkova G, Thomson J.O, Janostakova A, Wang S, Parsons S, Fischer P.M, Zhelev N.Z, Hajduch M. New lupane derived compounds with pro-apoptotic activity in cancer cells: synthesis and structure-activity relationships J Med Chem 2003 vol. 46(25) p 5402

Peter M. Fischer, Shudong Wang, Nikolai Zhelev. Carrier based drug delivery system. US6472507 B1; Oct 29, 2002

McClue S.J, Blake D, Clarke R, Cowan A, Cummings L, Fischer P.M, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, Lane DP. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer. 2002 vol. 102(5) p 463

Zheleva D.I., McInnes C., Gavine A.L.., Zhelev N.Z., Fischer P.M., Lane D.P. Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A. J Pept Res 2002 vol. 60(5) p 257

McClue S., Fischer P.M, Blake D, Clarke R, Duff S., Krauss E., Cummings L, Stewart K, Melville J, Wang S, Zhelev N, Zheleva D. Studies on the mechanism of action of CYC202 (R-roscovitine). Proc  AACR 2002 vol. 43 p 666

Wang S., Blake D., Clarke R., Duff S., McClue S., McInnes C., Melville J., Stewart K., Taylor P., Westwood R., Wood G., Wu S.., Zhelev N.Z.; Zheleva D. I.; Walkinshaw M., Lane D. P.; Fischer P. M. 4-Heteroaryl-2-phenylamino-pyrimidines, a new class of CDK2 inhibitors: Discovery, optimization, and antiproliferative activity in vitro and in vivo. Proc  AACR 2002 vol. 43 p 848

Fischer P.M., Zheleva D.I., McInnes C., Gavine A.L., Zhelev N.Z., Lane D.P. Peptide inhibitors of cyclin-dependent kinases derived from p21(WAF1): delineation and structural insight into their interactions with cyclin A. Clin Cancer Res. 2001 vol 7 (11) p 3821

Whittaker, S., Walton, M., Kelland, L., Garrett, M., Zhelev, N. and  Workman, P. Rb Phorphorylation as a pharmacodynamic marker of Roscovitine (CYC202) activity in vitro and in vivo. Proc  AACR  2001  vol 42, p 926.

Kovarova H., Hajduch M., Korinkova G., Halada P., Krupickova S., Gouldsworthy A. Zhelev N.Z and Strnad M. Proteomics approach in classifying the biochemical basis of the anti-cancer activity of a new olomoucine-derived synthetic cyclin dependent kinase inhibitor, bohemine.  Electrophoresis 2000  vol. 21, p 3757.

Zheleva D. I., Zhelev N. Z., Fischer P. M., Duff S.V.,  Warbrick E,  Blake D. G., and Lane, D. P A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA - affinity, stoichiometry, and thermodynamics. Biochemistry  2000 vol.39(25), p 7388.

Zheleva D. I., Fischer P.M., Zhelev N. Z., Melville J. E., Gavine A-L., and Lane D. P. Design of cell-permeable peptides inhibitors of cyclin D1/ CDK4 complex. M Nature Biotech Sh R 2000   vol. 11, p 25

Zhelev N. Z., Zheleva D. I., Fischer P.M., Duff S.V., and Lane D. P. Growth inhibitory effect of peptides derived from the C-terminal domain of P21waf is mediated by cyclin D1/CDK4 inhibition: PCNA binding is not essential. M Nature Biotech Sh R 2000)  vol. 11, p 22

Zheleva D. I., Zhelev N. Z., Fischer P.M., Duff S.V., Chan W., Gouldsworthy A. M., and Lane D. P. Affinity capture method for identification of peptide inhibitors of cyclin dependent kinases. M Nature Biotech Sh R 2000  vol. 11, p 83

Fischer P. M., Zhelev N. Z., Wang S., Melville, J. E., Fåhraeus R., and Lane, D. P. Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin. J. Peptide Res. 2000  vol. 55 (2), p 163 .

Fischer P. M., Zhelev N. Z., Fåhraeus R., Ball K. L., Warbrick E., and Lane, D. P.  Intracellular delivery of cell-cycle inhibitor peptides by Penetratin, a 16-residue peptide from the Antennapedia homeoprotein. In Peptides 1998, (Bajusz S., and Hudecz F., Eds.), p 700.

Zhelev N. Zh., Barratt M. J. and Mahadevan L. C. Use of reversed-phase high-performance liquid chromatography on polystyrene-divinylbenzene columns for the rapid separation and purification of acid-soluble nuclear proteins. J Chromatogr. 1997. vol. 763, p 65 

Zhelev N.Zh., Buckle R., Snyder D. and Marsh P. Studying of protein-DNA binding by dynamic light scattering. Cell Mol Biol L 1996 vol. 1(2), p 199.

Zatsepina O. V., Zhelev N. Zh. and Jordan E. G. Immunolocalization of nucleolar protein B23 in mitotic centrosomes. Mol Biol 1995  vol. 29(6), p1359

Barratt M. J., Hazzalin C. A., Zhelev N. Zh. and Mahadevan L. C.  A mitogen- and anisomycin- stimulated kinase phosphorylates HMG14 in its basic amino-terminal domain in vivo and on isolated mononucleosomes. EMBO J 1994 vol. 13(19), p 4524.

Kardalinou E., Zhelev N. Zh., Hazzalin C. A. and Mahadevan L. C. Anisomycin and rapamycin define an area upstream of p70/85 S6K containing a bifurcation to histone H3-HMG-like protein phosphorylation and c-fos, c-jun induction. Mol Cell Biol 1994 vol. 14(2), p 1066 

Zhelev N. Zh., Kardalinou, E., Hazzalin C. A., Cano E., Barratt M. J. and Mahadevan L.C. Signalling to chromatin and the superinduction of proto-oncogenes. Biochem Soc Trans 1993   vol. 21, p 907.

Kicheva, M. I.; Zhelev, N. Zh.; Popova, L. P. Effect of water stress on protein synthesis in two wheat cultivars differing in drought tolerance. C R Acad Sci Bulg 1993 vol. 46(3), p 95.

Miteva T. S., Zhelev N. Zh. and Popova L. P. Effect of salinity on the synthesis of ribulose-1,5,-bisphosphate carboxylase/oxygenase in barley leaves. J Plant Physiol 1992 vol. 140(1), p 46.

Zhelev N. Zh., Bachvarova N. N. and Chelibonova-Lorer H. O-Glycosylation of total cellular proteins during the cell cycle. C R Acad Sci  Bulg 1992 vol. 45(1), p 73.

Zhelev, N.Zh., Todorov, I.T. Philipova, R.N., and Hadjiolov, A.A. Phosphorylation-related accumulation of the 125K nuclear matrix protein mitotin in human mitotic cells. J Cell Sci 1990 vol. 95, p 59 

Pironcheva, G.L., Semionov, E.P., and Zhelev, N.Zh. Heat shock reaction in cells. Adv Molec Biol 1989 vol. 8, p 73.

Zhelev, N.Zh., Philipova, R.N., Todorov, I.T. and Hadjiolov, A.A. Differential stability of the 125 kDa nuclear matrix protein mitotin in the cell cycle. C. R. Acad. Sci. Bulg. 1989  vol. 42(11), p 103.

Pironcheva, G., Zhelev, N.Zh., and Russev, G. Isolation of U5 snRNP particles. Cytobios 1988 vol. 56, p39.

Todorov, I.T., Philipova, R.N., Zhelev, N.Zh. and Hadjiolov, A.A. Changes in a nuclear matrix antigen during the cell cycle: interphase and mitotic cells. Biol Cell 1988 vol. 62, p 105.

Philipova, R. N., Zhelev, N. Zh., Todorov, I. T. and Hadjiolov, A. A.  Monoclonal antibody against a nuclear matrix antigen in proliferating cell. Biol Cell 1987 vol.60, p 1.

Todorov, I. T., Philipova, R. N., Zhelev, N. Zh. and Hadjiolov, A. A.  Monoclonal antibody to a nuclear antigen of human B-lymphoblastoid cells. Cell Biol Int  Rep 1987 vol.11(3), p 181




Fellow of the Royal Society of Biology (UK)

Fellow of the Institute of Biology (UK)

Full Member of the Bulgarian National Academy of Medicine

Doctor Honoris Causa (Medical University Plovdiv)

Signum Honoris (Medical University Sofia)

Medal, International Board for Academic Entrepreneurship (Varna Free University)

Professional Activities

2016 - present Editor, SDRP Journal of Cellular and Molecular Physiology

2016 - present Editor, Henry Journal of Cardiology & Cardiovascular Medicine

2015 - present Editor, EuroBiotech Journal

2015 - present Editorial Board, Mathews Journal of Cardiology

2015 - present Editorial Board, Austin Biology

2015 - present Editorial Board, AIMS Bioengineering

2015 - present  Editorial Board, Journal of Molecular Medicine

2015 - present  Editorial Board, Journal of Basic Medical Sciences

2014 - present  President, European BioDiscovery Federation

2014 - present  Editorial Board, EC Cancer Journal

2014 - present  Editorial Board, Journal of Molecular Engineering & Systems Biology

2012 - present   Managing Editor, BioDiscovery

2011 - present   Visiting Professor, Fujian University of Traditional Chinese Medicine

2008 - present   Reviewer of research grant proposals for Medical Research Council (MRC), UK;  National Centre for Research and Development (NCBR), Poland; National Science Fund (NSF), Bulgaria; The Cargegie Trust, UK,  the Netherlands Organisation for Scientific Research, BBSRC, UK and Kentucky Science and Engineering Foundation, USA.

2005 - present   Editor, Medicine and Sport

2005 - present   Editorial Board, Biotechnology and Biotechnological Equipment

2004 - present   Editor, Zone4science

2003 - present   Visiting Professor, Fujian Medical University

2003 - 2005       Honorary Professor, Xiamen Medical University

2003 - present   Honorary Professor, Technical University of Varna

2002 - 2004       Visiting Professor, Wuhan Institute of Botany, Chinese Academy of Sciences

2002 - present   Editor, Technology in Cancer Research and Treatment

1992 - present   Journal Referee for: Cytobios, Adv. Molec. Biol, J. Cell Sci, Cell Biol. Int. Rep, Biol. Cell, C. R. Acad. Sci. Bulg, Oncologos, Medicine and Sport,  Biotechnol. & Biotechnol. Eq, Zone4science, Technology in Cancer Research and Treatment, Cancer Research Frontiers, BioDiscovery, Advances in Biology, Biotechnology and Genetics, International Journal of Cardiology (IJC) Heart & Vasculature, Toxins, Frontiers Physiology, Science.


2003 - 2012      Honorary Consul General for Bulgaria in Scotland

2007 - 2013      Chair, Slavic and Eastern European Institute, Scotland


My group has received research funding from the Scottish Enterprise, Royal Society of Edinburgh, Socrates Erasmus, Carnegie Trust, the UK Government, Medical Research Scotland, Innovation Portal, Dr Hadwen Trust and Northwood Trust.